These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15246277)

  • 1. Effect of polyanion-resistance on HIV-1 infection.
    Bobardt MD; Armand-Ugón M; Clotet I; Zhang Z; David G; Este JA; Gallay PA
    Virology; 2004 Aug; 325(2):389-98. PubMed ID: 15246277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-HIV activity of ADS-J1 targets the HIV-1 gp120.
    Armand-Ugón M; Clotet-Codina I; Tintori C; Manetti F; Clotet B; Botta M; Esté JA
    Virology; 2005 Dec; 343(1):141-9. PubMed ID: 16168454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures.
    Szabó J; Cervenák L; Tóth FD; Prohászka Z; Horváth L; Kerekes K; Beck Z; Bácsi A; Erdei A; Peerschke EI; Füst G; Ghebrehiwet B
    Clin Immunol; 2001 May; 99(2):222-31. PubMed ID: 11318594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid.
    Zhou J; Chen CH; Aiken C
    Retrovirology; 2004 Jun; 1():15. PubMed ID: 15225375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
    Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
    AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypic coreceptor analysis.
    Sierra S; Kaiser R; Thielen A; Lengauer T
    Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R5- and X4-HIV-1 use differentially the endometrial epithelial cells HEC-1A to ensure their own spread: implication for mechanisms of sexual transmission.
    Saïdi H; Magri G; Nasreddine N; Réquena M; Bélec L
    Virology; 2007 Feb; 358(1):55-68. PubMed ID: 16934308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection.
    Fontenot D; Jones JK; Hossain MM; Nehete PN; Vela EM; Dwyer VA; Jagannadha Sastry K
    Virology; 2007 Jun; 363(1):69-78. PubMed ID: 17320923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of HIV-1 with dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-expressing cells is influenced by gp120 envelope modifications associated with disease progression.
    Nabatov AA; van Montfort T; Geijtenbeek TB; Pollakis G; Paxton WA
    FEBS J; 2006 Nov; 273(21):4944-58. PubMed ID: 17010165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
    Hamza A; Zhan CG
    J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
    Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
    Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
    Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
    Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks.
    Sáez-Cirión A; Versmisse P; Truong LX; Chakrabarti LA; Carpentier W; Barré-Sinoussi F; Scott-Algara D; Pancino G
    Retrovirology; 2006 Nov; 3():81. PubMed ID: 17092330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for positive selection driving the evolution of HIV-1 env under potent antiviral therapy.
    Frost SD; Günthard HF; Wong JK; Havlir D; Richman DD; Leigh Brown AJ
    Virology; 2001 Jun; 284(2):250-8. PubMed ID: 11384224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
    Bosch B; Blanco J; Pauls E; Clotet-Codina I; Armand-Ugón M; Grigorov B; Muriaux D; Clotet B; Darlix JL; Esté JA
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4296-304. PubMed ID: 16189111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
    Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
    J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
    Auwerx J; François KO; Covens K; Van Laethem K; Balzarini J
    Virology; 2008 Dec; 382(1):10-9. PubMed ID: 18930512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for the interaction between focal adhesion kinase and CD4.
    Garron ML; Arthos J; Guichou JF; McNally J; Cicala C; Arold ST
    J Mol Biol; 2008 Feb; 375(5):1320-8. PubMed ID: 18078954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.